Literature DB >> 29266077

ACOG Committee Opinion No. 727: Cascade Testing: Testing Women for Known Hereditary Genetic Mutations Associated With Cancer.

.   

Abstract

"Cascade testing" refers to the performance of genetic counseling and testing in blood relatives of individuals who have been identified with specific genetic mutations. Testing protocols and other interventions may save lives and improve health and quality of life for these family members. Obstetrician-gynecologists should know who is eligible for cascade testing and should use all available resources to ensure that cascade testing is offered and occurs in a timely manner. Despite the clear health benefits for specific populations and individuals, obstetrician-gynecologists should be aware of the potential barriers to cascade testing and should know which options can help patients overcome those barriers. Such barriers, however, may be overcome with health care provider awareness and participation in local and state initiatives to improve implementation of cascade testing. Resources (available within federal and state agencies, professional societies, and in advocacy and community groups) are critical to the successful implementation of cascade testing. This Committee Opinion focuses specifically on cascade testing and the role of the obstetrician-gynecologist in clinical and public health efforts to increase identification of women with hereditary cancer syndromes.

Entities:  

Mesh:

Year:  2018        PMID: 29266077     DOI: 10.1097/AOG.0000000000002457

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  7 in total

Review 1.  Disparities in gynecologic cancer genetics evaluation.

Authors:  Emily M Hinchcliff; Erica M Bednar; Karen H Lu; J Alejandro Rauh-Hain
Journal:  Gynecol Oncol       Date:  2019-01-31       Impact factor: 5.482

2.  Prospective Feasibility Trial of a Novel Strategy of Facilitated Cascade Genetic Testing Using Telephone Counseling.

Authors:  Melissa K Frey; Ryan M Kahn; Eloise Chapman-Davis; Francesca Tubito; Maira Pires; Paul Christos; Samantha Anderson; Semanti Mukherjee; Bailey Jordan; Stephanie V Blank; Thomas A Caputo; Ravi N Sharaf; Kenneth Offit; Kevin Holcomb; Steven Lipkin
Journal:  J Clin Oncol       Date:  2020-01-10       Impact factor: 44.544

3.  Outcomes of incidentally detected ovarian cancers diagnosed at time of risk-reducing salpingo-oophorectomy in BRCA mutation carriers.

Authors:  Renee Cowan; Silvana Pedra Nobre; Nisha Pradhan; Maya Yasukawa; Qin C Zhou; Alexia Iasonos; Robert A Soslow; Angela G Arnold; Magan Trottier; Amanda Catchings; Kara Long Roche; Ginger Gardner; Mark Robson; Nadeem R Abu Rustum; Carol Aghajanian; Karen Cadoo
Journal:  Gynecol Oncol       Date:  2021-03-10       Impact factor: 5.304

4.  A family pedigree of malignancies associated with BRCA1 pathogenic variants: a reflection of the state of art in China.

Authors:  Wenhui Li; Lei Li; Ming Wu
Journal:  Hered Cancer Clin Pract       Date:  2019-09-10       Impact factor: 2.857

Review 5.  Challenges of Genomic Testing for Hereditary Breast and Ovarian Cancers.

Authors:  Lindsey McAlarnen; Kristen Stearns; Denise Uyar
Journal:  Appl Clin Genet       Date:  2021-01-14

6.  IMProving care After inherited Cancer Testing (IMPACT) study: protocol of a randomized trial evaluating the efficacy of two interventions designed to improve cancer risk management and family communication of genetic test results.

Authors:  Deborah Cragun; Jason Beckstead; Meagan Farmer; Gillian Hooker; Marleah Dean; Ellen Matloff; Sonya Reid; Ann Tezak; Anne Weidner; Jennifer G Whisenant; Tuya Pal
Journal:  BMC Cancer       Date:  2021-10-13       Impact factor: 4.430

7.  Feasibility of targeted cascade genetic testing in the family members of BRCA1/2 gene pathogenic variant/likely pathogenic variant carriers.

Authors:  Jeeyeon Lee; Ji Yeon Ham; Ho Yong Park; Jin Hyang Jung; Wan Wook Kim; Byeongju Kang; Yee Soo Chae; Soo Jung Lee; In Hee Lee; Nan Young Lee
Journal:  Sci Rep       Date:  2022-02-03       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.